American Journal of Cardiovascular Drugs

, Volume 4, Issue 4, pp 227–246 | Cite as

Dyslipidemia in Visceral Obesity

Mechanisms, Implications, and Therapy
  • Dick C. Chan
  • Hugh P. R. Barrett
  • Gerald F. Watts
Review Article


Visceral obesity is frequently associated with high plasma triglycerides and low plasma high density lipoprotein-cholesterol (HDL-C), and with high plasma concentrations of apolipoprotein B (apoB)-containing lipoproteins. Atherogenic dyslipidemia in these patients may be caused by a combination of overproduction of very low density lipoprotein (VLDL) apoB-100, decreased catabolism of apoB-containing particles, and increased catabolism of HDL-apoA-I particles. These abnormalities may be consequent on a global metabolic effect of insulin resistance. Weight reduction, increased physical activity, and moderate alcohol intake are first-line therapies to improve lipid abnormalities in visceral obesity. These lifestyle changes can effectively reduce plasma triglycerides and low density lipoprotein-cholesterol (LDL-C), and raise HDL-C. Kinetic studies show that in visceral obesity, weight loss reduces VLDL-apoB secretion and reciprocally upregulates LDL-apoB catabolism, probably owing to reduced visceral fat mass, enhanced insulin sensitivity and decreased hepatic lipogenesis. Adjunctive pharmacologic treatments, such as HMG-CoA reductase inhibitors, fibric acid derivatives, niacin (nicotinic acid), or fish oils, may often be required to further correct the dyslipidemia. Therapeutic improvements in lipid and lipoprotein profiles in visceral obesity can be achieved by several mechanisms of action, including decreased secretion and increased catabolism of apoB, as well as increased secretion and decreased catabolism of apoA-I. Clinical trials have provided evidence supporting the use of HMG-CoA reductase inhibitors and fibric acid derivatives to treat dyslipidemia in patients with visceral obesity, insulin resistance and type 2 diabetes mellitus. Since drug monotherapy may not adequately optimize dyslipoproteinemia, dual pharmacotherapy may be required, such as HMG-CoA reductase inhibitor/fibric acid derivative, HMG-CoA reductase inhibitor/niacin and HMG-CoA reductase inhibitor/fish oils combinations. Newer therapies, such as cholesterol absorption inhibitors, cholesteryl ester transfer protein antagonists and insulin sensitizers, could also be employed alone or in combination with other agents to optimize treatment. The basis for a multiple approach to correcting dyslipoproteinemia in visceral obesity and the metabolic syndrome relies on understanding the mechanisms of action of the individual therapeutic components.


Cholesteryl Ester Transfer Protein Visceral Obesity Fibric Acid Derivative Intermediate Density Lipoprotein Chylomicron Remnant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by grants from the National Health and Medical Research Council, the National Heart Foundation and the National Institutes of Health (NIBIB P41 EB-001975). Support was also provided by the Raine Medical Research Foundation, the Royal Perth Hospital Medical Research Foundation, Pfizer. HPR Barrett is a Career Development Fellow of the National Heart Foundation.


  1. 1.
    Bjorntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493–6PubMedCrossRefGoogle Scholar
  2. 2.
    Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998; 9: 473–81PubMedCrossRefGoogle Scholar
  3. 3.
    Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arterioscler Thromb Vasc Biol 1990; 10: 497–511CrossRefGoogle Scholar
  4. 4.
    Borkan GA, Gerzof SG, Robbins AH, et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36: 172–7PubMedGoogle Scholar
  5. 5.
    Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRefGoogle Scholar
  6. 6.
    Definition, diagnosis and classification of diabetes mellitus and its complication: Report of a WHO consultation. Geneva, Department of Noncommunicable Disease Surveillance, World Health Organization. 1999Google Scholar
  7. 7.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9PubMedCrossRefGoogle Scholar
  8. 8.
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16PubMedCrossRefGoogle Scholar
  9. 9.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9PubMedCrossRefGoogle Scholar
  10. 10.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697–738PubMedCrossRefGoogle Scholar
  11. 11.
    Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 Suppl. 3: 24–34PubMedCrossRefGoogle Scholar
  12. 12.
    Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor-α in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95(5): 2111–21PubMedCrossRefGoogle Scholar
  13. 13.
    Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119–25PubMedCrossRefGoogle Scholar
  14. 14.
    Nonogaki K, Fuller GM, Fuentes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136: 2143–9PubMedCrossRefGoogle Scholar
  15. 15.
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607PubMedCrossRefGoogle Scholar
  16. 16.
    Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med 2001; 226: 13–26Google Scholar
  17. 17.
    Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81PubMedCrossRefGoogle Scholar
  18. 18.
    McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7–18PubMedCrossRefGoogle Scholar
  19. 19.
    Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201–29PubMedCrossRefGoogle Scholar
  20. 20.
    Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447–52PubMedCrossRefGoogle Scholar
  21. 21.
    Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179–84PubMedCrossRefGoogle Scholar
  22. 22.
    Grundy SM. Metabolic complications of obesity. Endocr J 2000; 13: 155–65CrossRefGoogle Scholar
  23. 23.
    McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713–8PubMedCrossRefGoogle Scholar
  24. 24.
    Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7: 325–31PubMedGoogle Scholar
  25. 25.
    Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31PubMedGoogle Scholar
  26. 26.
    Panarotto D, Remillard P, Bouffard L, et al. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84–92PubMedCrossRefGoogle Scholar
  27. 27.
    Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state. Diabetes Care 1996; 19: 390–3PubMedCrossRefGoogle Scholar
  28. 28.
    Watts GF, Chan DC, Barrett PHR, et al. Adipose tissue compartments and VLDL apolipoprotein B-100 kinetics in overweight-obese men. Obes Res 2003; 11: 152–9PubMedCrossRefGoogle Scholar
  29. 29.
    Riches FM, Watts GF, Naoumova RP, et al. Hepatic secretion of very-low density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998; 22: 414–23PubMedCrossRefGoogle Scholar
  30. 30.
    Chan DC, Watts GF, Barrett PH, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002; 48: 278–83PubMedGoogle Scholar
  31. 31.
    Mekki N, Christofilis MA, Charbonnier M, et al. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab 1999; 84: 184–91PubMedCrossRefGoogle Scholar
  32. 32.
    Ginsberg HN, Illingworth DR. Postprandial dyslipiemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88(6A): 9H–15HPubMedCrossRefGoogle Scholar
  33. 33.
    Karpe F, de Faire U, Mercuri M, et al. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclersosis 1998; 141: 307–14CrossRefGoogle Scholar
  34. 34.
    Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38: 2173–92PubMedGoogle Scholar
  35. 35.
    Marno JC, Watts GF, Barrett PH, et al. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol 2001; 81: 626–32Google Scholar
  36. 36.
    Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060–8PubMedCrossRefGoogle Scholar
  37. 37.
    Kobayashi J, Tashiro J, Murano S, et al. Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol 1998; 48: 515–20CrossRefGoogle Scholar
  38. 38.
    Redgrave TG, Martins IJ, Mortimer BC. Measurement of expired carbon dioxide to access the metabolism of remnant lipoproteins. J Lipid Res 1995; 36: 2670–5PubMedGoogle Scholar
  39. 39.
    Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance: evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002; 277: 31646–55PubMedCrossRefGoogle Scholar
  40. 40.
    Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol 1999; 22: II1–6PubMedGoogle Scholar
  41. 41.
    Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–9PubMedCrossRefGoogle Scholar
  42. 42.
    Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029–36PubMedCrossRefGoogle Scholar
  43. 43.
    Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997; 8: 146–53PubMedCrossRefGoogle Scholar
  44. 44.
    Chan DC, Watts GF, Redgrave TG, et al. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002; 29: 1041–6CrossRefGoogle Scholar
  45. 45.
    Riches FM, Watts GF, van Bockxmeer FM, et al. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J Lipid Res 1998; 39: 1752–8PubMedGoogle Scholar
  46. 46.
    Watts GF, Riches FM, Humphries SE, et al. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 2000; 41: 481–8PubMedGoogle Scholar
  47. 47.
    Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002; 43: 1997–2006PubMedCrossRefGoogle Scholar
  48. 48.
    Wittrup HH, Hansen AT, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation 1999; 99: 2901–7PubMedCrossRefGoogle Scholar
  49. 49.
    Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022–6PubMedCrossRefGoogle Scholar
  50. 50.
    Krauss RM, Herbert PN, Levy RI, et al. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res 1973; 33: 403–11PubMedCrossRefGoogle Scholar
  51. 51.
    Lemieux S, Prud’homme D, Moorjani S, et al. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Atherosclerosis 1995; 118: 155–64PubMedCrossRefGoogle Scholar
  52. 52.
    Austin MA. Triglyceride, small, dense low density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200–7PubMedCrossRefGoogle Scholar
  53. 53.
    Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241–53PubMedCrossRefGoogle Scholar
  54. 54.
    Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260(13): 1917–21PubMedCrossRefGoogle Scholar
  55. 55.
    Gardner CD, Fortmann SP, Krauss RM. Association of small low density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875–81PubMedCrossRefGoogle Scholar
  56. 56.
    Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062–71PubMedCrossRefGoogle Scholar
  57. 57.
    Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002; 252: 440–7PubMedCrossRefGoogle Scholar
  58. 58.
    Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63: 1–11PubMedCrossRefGoogle Scholar
  59. 59.
    Ailhaud G, Fukamizu A, Massiera F, et al. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes 2000; 24 Suppl. 4: S33–5CrossRefGoogle Scholar
  60. 60.
    Keidar S, Kaplan M, Hoffman A, et al. Angiotensin II stimulates macrophagemediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201–15PubMedCrossRefGoogle Scholar
  61. 61.
    Fielding C, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211–28PubMedGoogle Scholar
  62. 62.
    Santamarina-Fojo S, Lambert G, Hoeg JM, et al. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2000; 11: 267–75PubMedCrossRefGoogle Scholar
  63. 63.
    Fournier N, Myara I, Atger V, et al. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high density lipoproteins (HDL). Clin Chim Acta 1995; 234: 47–61PubMedCrossRefGoogle Scholar
  64. 64.
    Gordon DJ, Prostfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8–15PubMedCrossRefGoogle Scholar
  65. 65.
    Assmann G, Schulte H, von Eckardstein A, et al. high density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11–20PubMedCrossRefGoogle Scholar
  66. 66.
    von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high density lipoprotein cholesterol? Curr Opin Lipidol 2000; 11: 627–37CrossRefGoogle Scholar
  67. 67.
    Lamarche B, Moorjani S, Cantin B, et al. Association of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098–105PubMedCrossRefGoogle Scholar
  68. 68.
    Pascot A, Lemieux I, Prud’homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007–14PubMedGoogle Scholar
  69. 69.
    Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999; 286: 145–61PubMedCrossRefGoogle Scholar
  70. 70.
    Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1819–28PubMedCrossRefGoogle Scholar
  71. 71.
    Pascot A, Lemieux I, Bergeron J, et al. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis 2002; 160: 399–406PubMedCrossRefGoogle Scholar
  72. 72.
    Pietzsch J, Julius U, Nitzsche S, et al. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47: 1928–34PubMedCrossRefGoogle Scholar
  73. 73.
    Frenais R, Ouguerram K, Maugeais C, et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 1997; 40: 578–83PubMedCrossRefGoogle Scholar
  74. 74.
    Pont F, Duvillard L, Florentin E, et al. high density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients: an in vivo stable isotope study. Int J Obes 2002; 26: 1151–8CrossRefGoogle Scholar
  75. 75.
    Watts GF, Barrett PHR, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803–11PubMedCrossRefGoogle Scholar
  76. 76.
    Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153: 263–72PubMedCrossRefGoogle Scholar
  77. 77.
    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8PubMedCrossRefGoogle Scholar
  78. 78.
    American Diabetes Association. Management of dyslipidaemia in adults with diabetes. Diabetes Care 2002; 25: S74–7CrossRefGoogle Scholar
  79. 79.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs high density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–8PubMedCrossRefGoogle Scholar
  80. 80.
    The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21–7CrossRefGoogle Scholar
  81. 81.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  82. 82.
    Srinivasan SR, Berenson GS. Apolipoproteins B and A-I as predictors of risk of coronary artery disease. Lancet 2001; 358: 2012–3PubMedCrossRefGoogle Scholar
  83. 83.
    Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–33PubMedCrossRefGoogle Scholar
  84. 84.
    Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128–41PubMedGoogle Scholar
  85. 85.
    Singh RB, Rastogi SS, Verna R, et al. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304: 1015–9PubMedCrossRefGoogle Scholar
  86. 86.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403PubMedCrossRefGoogle Scholar
  87. 87.
    Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5–9PubMedGoogle Scholar
  88. 88.
    Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56: 320–8PubMedGoogle Scholar
  89. 89.
    Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84: 2854–61PubMedCrossRefGoogle Scholar
  90. 90.
    Siscovick DS, Ekelund LG, Hyde JS, et al. Physical activity and coronary heart disease among asymptomatic hypercholesterolemic men (the Lipid Research Clinics Coronary Primary Prevention Trial). Am J Public Health 1988; 78: 1428–31PubMedCrossRefGoogle Scholar
  91. 91.
    Westheim A, Os I. Physical activity and the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992; 20 Suppl. 8: S49–53PubMedGoogle Scholar
  92. 92.
    Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21: 1226–32PubMedCrossRefGoogle Scholar
  93. 93.
    Haibert JA, Silagy CA, Finucane P, et al. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 1999; 53: 514–22CrossRefGoogle Scholar
  94. 94.
    Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis 1998; 137: 215–21PubMedCrossRefGoogle Scholar
  95. 95.
    Stefanick ML. Physical activity for preventing and treating obesity-related dislipoproteinemias. Med Sci Sport Exerc 1999; 31: S609–18CrossRefGoogle Scholar
  96. 96.
    Pearson TA. Alcohol and heart disease. Circulation 1996; 94: 3023–5PubMedCrossRefGoogle Scholar
  97. 97.
    De Oliveira E, Silva ER, Foster D, McGee Harper M, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation 2000; 102: 2347–52CrossRefGoogle Scholar
  98. 98.
    Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta 1985; 152: 281–8PubMedCrossRefGoogle Scholar
  99. 99.
    Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002; 143: 356–65PubMedCrossRefGoogle Scholar
  100. 100.
    Mori TA, Beilin LJ. Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001; 12: 11–7PubMedCrossRefGoogle Scholar
  101. 101.
    Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747–57PubMedCrossRefGoogle Scholar
  102. 102.
    Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085–94PubMedGoogle Scholar
  103. 103.
    Dunstan DW, Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake or serum lipids and glycemic control in NIDDM: a randomized controlled study. Diabetes Care 1997; 20: 913–21PubMedCrossRefGoogle Scholar
  104. 104.
    EUROASPIRE I and II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principle results from EUROASPIRE II Euro Heart Survey. Eur Heart J 2001; 22: 554–72CrossRefGoogle Scholar
  105. 105.
    Pearson TA, McBride PE, Miller NH, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task Force 8. organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039–47PubMedCrossRefGoogle Scholar
  106. 106.
    Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665–72PubMedCrossRefGoogle Scholar
  107. 107.
    Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  108. 108.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513–9PubMedCrossRefGoogle Scholar
  109. 109.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  110. 110.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22CrossRefGoogle Scholar
  111. 111.
    The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRefGoogle Scholar
  112. 112.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  113. 113.
    Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661–7PubMedCrossRefGoogle Scholar
  114. 114.
    Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–92PubMedCrossRefGoogle Scholar
  115. 115.
    Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046–51PubMedCrossRefGoogle Scholar
  116. 116.
    Collins R, Armitage J, Sleigh P, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16PubMedCrossRefGoogle Scholar
  117. 117.
    Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 1998; 141: 203–7PubMedCrossRefGoogle Scholar
  118. 118.
    Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51: 2377–86PubMedCrossRefGoogle Scholar
  119. 119.
    Watts GF, Chan DC, Barrett PHR, et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 2003 Jul; 27(7): 862–5PubMedCrossRefGoogle Scholar
  120. 120.
    Geneieve M, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rhosignaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001; 107: 1423–32CrossRefGoogle Scholar
  121. 121.
    Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424–8PubMedCrossRefGoogle Scholar
  122. 122.
    Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383–90PubMedCrossRefGoogle Scholar
  123. 123.
    Qin S, Koga T, Ganji SH, et al. Rosuvastatin stimulates apolipoprotein AI synthesis but not HDL catabolism by cultured human hepatocytes [abstract] 4th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology. May 8–10, 2003, Washington DC, USA. 2003, 255Google Scholar
  124. 124.
    Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561–74PubMedCrossRefGoogle Scholar
  125. 125.
    Fruchart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002; 13: 605–16PubMedCrossRefGoogle Scholar
  126. 126.
    Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995; 92: 1779–85PubMedCrossRefGoogle Scholar
  127. 127.
    The Diabetes Atherosclerosis Intervention Study. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: a randomised study. Lancet 2001; 357: 905–10CrossRefGoogle Scholar
  128. 128.
    Fruchart JC, Staels B, Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res 2001; 44: 345–52PubMedCrossRefGoogle Scholar
  129. 129.
    Robins SJ. PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates. J Cardiovas Risk 2001; 8: 195–201CrossRefGoogle Scholar
  130. 130.
    Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atherosclerosis Rep 2001; 3: 83–92CrossRefGoogle Scholar
  131. 131.
    Berge J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–35CrossRefGoogle Scholar
  132. 132.
    Bocher V, Millatt LJ, Fruchart JC, et al. Liver X receptors: new players in atherogenesis? Curr Opin Lipidol 2003; 14: 137–43PubMedCrossRefGoogle Scholar
  133. 133.
    Forcheron F, Cachefo A, Thevenon S, et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002; 51: 3486–91PubMedCrossRefGoogle Scholar
  134. 134.
    Roglans N, Peris C, Verd JC, et al. Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats. Biochem Pharmacol 2001; 62: 803–9PubMedCrossRefGoogle Scholar
  135. 135.
    Blane GF. Comparative toxicity and safety profile of fenofibrate and othe fibric acid derivatives. Am J Med 1987; 83: 26–36PubMedCrossRefGoogle Scholar
  136. 136.
    The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–74CrossRefGoogle Scholar
  137. 137.
    Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563–9PubMedCrossRefGoogle Scholar
  138. 138.
    Grundy SM, Ahrens EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94–121PubMedGoogle Scholar
  139. 139.
    Crouse III JR. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243–8PubMedCrossRefGoogle Scholar
  140. 140.
    Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atherosclerosis Rep 2001; 3: 74–82CrossRefGoogle Scholar
  141. 141.
    Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998; 82: 18U–23UPubMedCrossRefGoogle Scholar
  142. 142.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55PubMedCrossRefGoogle Scholar
  143. 143.
    SoRelle R. Niacin-simvastatin combination benefits patients with coronary artery disease. Circulation 2001; 104: E9050–60CrossRefGoogle Scholar
  144. 144.
    Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000; 2: 26–46CrossRefGoogle Scholar
  145. 145.
    Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992, 77-81Google Scholar
  146. 146.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263–70PubMedCrossRefGoogle Scholar
  147. 147.
    Grundy SM, Vega G, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568–76PubMedCrossRefGoogle Scholar
  148. 148.
    Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755–8PubMedCrossRefGoogle Scholar
  149. 149.
    Angerer P, von Schacky C. n-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol 2000; 11: 57–63PubMedCrossRefGoogle Scholar
  150. 150.
    Nordoy A. Fish consumption and cardiovascular diseases. Eur Heart J 2001; 3: D4–7CrossRefGoogle Scholar
  151. 151.
    Harris WS, Isley WL. Clinical trial evidence for the cardioprotective effects of omega-3-fatty acids. Curr Atheroscler Rep 2001; 3: 174–9PubMedCrossRefGoogle Scholar
  152. 152.
    GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–55CrossRefGoogle Scholar
  153. 153.
    von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130: 554–62Google Scholar
  154. 154.
    de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779–85PubMedCrossRefGoogle Scholar
  155. 155.
    Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol 2000; 11: 3–7PubMedCrossRefGoogle Scholar
  156. 156.
    Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007–15PubMedGoogle Scholar
  157. 157.
    Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002; 32: 429–36PubMedCrossRefGoogle Scholar
  158. 158.
    Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74: 82–9PubMedCrossRefGoogle Scholar
  159. 159.
    Bordin P, Bodamer OA, Venkatesan S, et al. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur J Clin Nutr 1998; 52: 104–9PubMedCrossRefGoogle Scholar
  160. 160.
    Chan DC, Watts GF, Mori TA, et al. Randomized controlled trial of the effect of n-3 fatty acids supplementation on apolipoprotein B-100 and chylomicron remnant metabolism in visceral obesity. Am J Clin Nutr 2003; 77: 300–9PubMedGoogle Scholar
  161. 161.
    Frenais R, Ouguerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 2001; 157: 131–5PubMedCrossRefGoogle Scholar
  162. 162.
    Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA 1998; 279: 1643–50PubMedCrossRefGoogle Scholar
  163. 163.
    Jacobson TA. Combination lipid-altering therapy: an emerging treatment paradigm for 21st century. Curr Atheroscler Rep 2001; 3: 373–82PubMedCrossRefGoogle Scholar
  164. 164.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608–13PubMedCrossRefGoogle Scholar
  165. 165.
    Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355–71PubMedCrossRefGoogle Scholar
  166. 166.
    Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672–8PubMedCrossRefGoogle Scholar
  167. 167.
    Bhatnagar D, Mackness MI, Durrinton PN. Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor. Eur Heart J 2001; 3: D53–8CrossRefGoogle Scholar
  168. 168.
    Millatt LJ, Bocher V, Fruchart JC, et al. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim Biophys Acta 2003; 1631: 107–18PubMedCrossRefGoogle Scholar
  169. 169.
    Kaplan F, Al-Majali K, Betteridge DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001; 8: 211–7PubMedCrossRefGoogle Scholar
  170. 170.
    Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25–33PubMedGoogle Scholar
  171. 171.
    United Kingdom Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854–65CrossRefGoogle Scholar
  172. 172.
    Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74PubMedGoogle Scholar
  173. 173.
    James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group: Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–25PubMedCrossRefGoogle Scholar
  174. 174.
    Watts GF, Herrmann S, Riches FM. Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. QJM 2000; 93: 153–61PubMedCrossRefGoogle Scholar
  175. 175.
    Snider LJ, Malone M. Orlistat use in type 2 diabetes. Ann Pharmacother 2002; 36: 1210–8PubMedCrossRefGoogle Scholar
  176. 176.
    Clifton P. Plant sterol and stanols-comparison and contrasts: sterol verse stanols in cholesterol-lowering: is there a difference. Atheroscler Suppl 2002; 3(3): S5–9CrossRefGoogle Scholar
  177. 177.
    Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulindependent diabetic men. J Lipid Res 1996; 37: 1776–85PubMedGoogle Scholar
  178. 178.
    Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37: 773–80PubMedCrossRefGoogle Scholar
  179. 179.
    Knopp RH, Gitter H, Truitt T. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729–41PubMedCrossRefGoogle Scholar
  180. 180.
    Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717–28PubMedCrossRefGoogle Scholar
  181. 181.
    Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90: 737–40PubMedCrossRefGoogle Scholar
  182. 182.
    Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol 1997; 17: 56–63PubMedCrossRefGoogle Scholar
  183. 183.
    Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose-response study. Circulation 2002; 105: 2159–65PubMedCrossRefGoogle Scholar
  184. 184.
    Barter PJ, Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 2001; 12: 377–82PubMedCrossRefGoogle Scholar
  185. 185.
    Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000; 293: 315–20PubMedGoogle Scholar
  186. 186.
    Huff MW, Telford DE, Edwards JY, et al. Inhibition of the apical sodiumdependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vas Biol 2002; 22: 1884–91CrossRefGoogle Scholar
  187. 187.
    Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453–8PubMedCrossRefGoogle Scholar
  188. 188.
    Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152–62PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Dick C. Chan
    • 1
  • Hugh P. R. Barrett
    • 1
  • Gerald F. Watts
    • 1
  1. 1.Lipoprotein Research Unit, School of Medicine and PharmacologyUniversity of Western Australia and The Western Australian Institute for Medical ResearchPerthAustralia

Personalised recommendations